Targeted TFO delivery to hepatic stellate cells.

Targeted TFO delivery to hepatic stellate cells.
复制标题

DOI:
10.1016/j.jconrel.2011.06.037
复制
发表时间:
2011-10-30
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
通讯作者:
Mahato RI
Mahato RI
中科院分区:
其他
文献类型:
--
作者:
Yang N;Singh S;Mahato RI

文献摘要

参考文献

被引文献

相似文献

三链体形成寡核苷酸(TFO)代表了通过与基因组DNA直接相互作用进行基因调控的反基因方法。虽然由于只有两个等位基因需要沉默来影响基因调控的事实,这种策略具有很大的前景,但将TFO体内递送到靶细胞仍然是一个挑战。我们最近的努力集中在将TFO与载体分子如胆固醇缀合以增强其细胞摄取和将甘露糖-6-磷酸-牛血清白蛋白(M6 P-BSA)缀合以靶向TFO递送至肝星状细胞(HSC)以治疗肝纤维化。然而,由于缺乏靶向递送(如脂质缀合物所见)和由于重复给予高分子量BSA缀合的TFO而引起的潜在免疫反应,这些方法变得不太有效。在这篇综述中,我们讨论了我们的最新努力,以提高TFO治疗肝纤维化的有效性。我们已经表明,将TFO与M6 P-HPMA缀合可以增强TFO向HSC的递送,并且具有通过抑制胶原蛋白合成来治疗肝纤维化的潜力。这种TFO缀合物由于使用HPMA(免疫原性最低的共聚物之一)而显示出可忽略的免疫原性,从而使其成为抗纤维化治疗的合适且更有效的候选物。
Triplex-forming oligonucleotides (TFOs) represent an antigene approach for gene regulation through direct interaction with genomic DNA. While this strategy holds great promise owing to the fact that only two alleles need silencing to impact gene regulation, delivering TFOs to target cells in vivo is still a challenge. Our recent efforts have focused on conjugating TFOs to carrier molecules like cholesterol to enhance their cellular uptake and mannose-6-phosphate-bovine serum albumin (M6P-BSA) to target TFO delivery to hepatic stellate cells (HSCs) for treating liver fibrosis. These approaches however are rendered less effective owing to a lack of targeted delivery, as seen with lipid-conjugates, and the potential immune reactions due to repeated dosing with high molecular weight BSA conjugated TFO. In this review, we discuss our latest efforts to enhance the effectiveness of TFO for treating liver fibrosis. We have shown that conjugation of TFOs to M6P-HPMA can enhance TFO delivery to HSCs and has the potential to treat liver fibrosis by inhibiting collagen synthesis. This TFO conjugate shows negligible immunogenicity owing to the use of HPMA, one of the least immunogenic copolymers, thereby making it a suitable and more effective candidate for antifibrotic therapy.
DOI: 10.1124/jpet.105.100347
发表时间: 2006-05-01
影响因子: 3.5
作者:
Cheng, K;Ye, ZY;Mahato, RI
通讯作者: Mahato, RI
DOI: 10.1126/science.290.5491.530
发表时间: 2000-10-20
期刊: SCIENCE
影响因子: 56.9
作者:
Vasquez, KM;Narayanan, L;Glazer, PM
通讯作者: Glazer, PM
DOI: 10.1021/mp9000469
发表时间: 2009-05
影响因子: 4.9
作者:
Cheng K;Yang N;Mahato RI
通讯作者: Mahato RI
DOI: 10.1182/blood.v89.8.2994
发表时间: 1997-04-15
期刊: BLOOD
影响因子: 20.3
作者:
Wooldridge, JE;Ballas, Z;Weiner, GJ
通讯作者: Weiner, GJ
DOI: 10.1007/s11095-011-0384-y
发表时间: 2011-04-01
影响因子: 3.7
作者:
Yang, Ningning;Mahato, Ram I.
通讯作者: Mahato, Ram I.